Recent Investment Analysts’ Ratings Updates for Bausch Health Companies (BHC)

A number of firms have modified their ratings and price targets on shares of Bausch Health Companies (NYSE: BHC) recently:

  • 5/21/2019 – Bausch Health Companies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $27.00 price target on the stock. According to Zacks, “Although Bausch’s performance in the first quarter was mixed, we are pretty encouraged by the increase in the company’s guidance. Growth in Xifaxan sales, the launch of Bryhali, the successful acquisition of Trulance and the approval of Duobrii should boost performance, going forward. Even though it is still early to comment on the rebuilding process, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable. Bausch repaid $100 million of debt in the first quarter of 2019 after repaying more than $1 billion in 2018. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far. “
  • 5/20/2019 – Bausch Health Companies was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 5/17/2019 – Bausch Health Companies was given a new $9.00 price target on by analysts at Wells Fargo & Co. They now have a “sell” rating on the stock.
  • 5/13/2019 – Bausch Health Companies was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating. They now have a $24.80 price target on the stock.
  • 5/8/2019 – Bausch Health Companies was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 5/7/2019 – Bausch Health Companies had its price target raised by analysts at Mizuho from $41.00 to $45.00. They now have a “buy” rating on the stock.
  • 4/25/2019 – Bausch Health Companies had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $32.00 price target on the stock. They wrote, “We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32.””
  • 4/13/2019 – Bausch Health Companies was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 4/5/2019 – Bausch Health Companies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $28.00 price target on the stock. According to Zacks, “Bausch has narrowed its focus on seven recently launched or expected to be launched products, pending completion of testing and receipt of FDA approval. The company's Salix business continues to drive growth and contribute to the top line. In particular, increased sales of Xifaxan are boosting the segment. Bausch started a rebuilding process after a tumultuous period. The company also changed its name. Even though it is still early to comment on the rebuilding process, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable. The company recorded 1% organic growth in 2018 and reduced debt by more than $1 billion. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the past three months. “
  • 4/2/2019 – Bausch Health Companies was given a new $28.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

Shares of NYSE BHC traded down $0.77 during midday trading on Thursday, reaching $23.67. 68,542 shares of the company were exchanged, compared to its average volume of 4,541,335. The stock has a market cap of $8.44 billion, a PE ratio of 5.89, a PEG ratio of 0.56 and a beta of 0.55. Bausch Health Companies Inc has a one year low of $17.20 and a one year high of $28.45. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.14. The firm had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The company’s revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.89 earnings per share. As a group, sell-side analysts predict that Bausch Health Companies Inc will post 4.15 earnings per share for the current fiscal year.

In related news, CEO Joseph C. Papa bought 30,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were purchased at an average price of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.87% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BHC. Bank of New York Mellon Corp bought a new stake in shares of Bausch Health Companies during the third quarter worth $9,358,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Bausch Health Companies by 44.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 191,569 shares of the company’s stock worth $3,542,000 after purchasing an additional 59,255 shares during the period. D.A. Davidson & CO. lifted its holdings in shares of Bausch Health Companies by 11.6% during the fourth quarter. D.A. Davidson & CO. now owns 18,210 shares of the company’s stock worth $336,000 after purchasing an additional 1,900 shares during the period. Dynamic Advisor Solutions LLC lifted its holdings in shares of Bausch Health Companies by 28.2% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 10,000 shares of the company’s stock worth $238,000 after purchasing an additional 2,199 shares during the period. Finally, Hayden Royal LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter worth $714,000. 54.30% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: Fundamental Analysis and Individual Investors

Receive News & Ratings for Bausch Health Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.